With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
This vaccination programme is based on the principles of priority groups to be vaccinated and health care workers both in the government and private sectors including ICDS workers will receive the vaccine during this phase.
The company is expecting tremendous growth and a better quarterly performance
Lasa Supergenerics Limited has received WHO GMP Certificate for its manufacturing facility situated at Khed in Ratnagiri.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
